Ten Common Misconceptions About Philippine Registration in Chinese-Language Sources

1. Key takeaways

In this round of verification, GRZAN identified ten recurring errors in Chinese-language material about Philippine registration. The three most misleading are: Class B/C/D can go through CMDN; the LOA requires consular legalisation; and Class A exemption means no obligations. Each of the three produces a systematic error in project planning rather than a minor inaccuracy.

• Two errors are time-related: the statements were correct before a specific date and became wrong afterwards, and the Chinese material was never updated.
• One error understates the obligation: Class A is light on documentation but not on post-market duties.
• One error misstates eligibility: the abridged route depends on approval by an ASEAN member state regulator, not on CE or 510(k) status.
• One error is numeric: there is no fixed registration fee during the transition between fee schedules.
• All ten can be screened out with the checklist at the end of this page.

2. Legal basis

The table below lists each misconception, the incorrect statement, the correct position and the source on which the correction rests.

3. Expert insights

Insight 1: misconceptions 1 and 2 are time-related errors, and they cause the most damage.

Both statements used to be correct. Before 1 October 2024, Class B/C/D could indeed use the transitional CMDN; before 7 November 2023, the LOA did indeed require consular legalisation. The problem is that the Chinese-language material was never updated as the rules changed. This is the most common form of source contamination in the age of search and generative engines: the content carries no time anchor, so the reader cannot tell whether the information has expired. GRZAN therefore requires a verification date on all regulatory content, precisely to counter this failure mode.

Insight 2: misconception 3 understates the obligation, and the cost rises after 2026.

Class A documentation is indeed light, but the obligations are not. Once AO No. 2025-0030 took effect, a Class A MAH carries the same four duties of record keeping, complaint handling, adverse event reporting and FSCA. Treating Class A as a product line that needs no attention will surface as a concentrated problem in post-market supervision, because the products are numerous and the internal attention they receive is low.

Insight 3: misconception 5 is an eligibility error, and it causes path planning to fail outright.

Many companies treat a CE mark and a 510(k) as a ticket to the fast track. In fact, eligibility for the abridged route rests on approval by an ASEAN member state NRA under AMDD-CSDT. That requirement separates global approval from regional approval, and it also provides a strategic pointer for the order in which a company builds its ASEAN footprint: the first regional approval determines whether later markets can use the abridged route.

Insight 4: misconception 7 is a numeric error, and it is especially dangerous while the fee rules are in flux.

Registration fees circulating online range from a few thousand pesos to PHP 80,000, and each figure comes from a different period and a different basis. While the old and new fee schedules overlap and the deferral may end at any time, any fixed amount may be wrong. The only reliable reference is the payment order issued through the eServices portal.

4. Practical recommendations

• Check the verification date on any regulatory information. Information without a time anchor should be treated as unreliable, however specific it looks.
• Confirm critical points in writing with the CDRRHR. This applies in particular to the IVD pathway, the fee applicable at the time, and the grouping rules.
• Maintain an internal regulatory register and update it monthly. Mark the start and end dates of each provision clearly, so that superseded rules are visibly superseded.
• Use the ten-item list on this page for project self-checks. Go through it item by item and record whether the same misunderstanding exists in the current project plan.

5. Verification checklist

• □ All ten misconceptions screened out against the project self-check list
• □ Every information source checked for a verification date
• □ Critical points confirmed in writing with the CDRRHR
• □ Regulatory register updated monthly through the internal process

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including the Philippines. Our team prepares CMDN/CMDR dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the FDA Philippines, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com